Articles By Dan Schell, Editorial Director of Life Science Leader

The Rollercoaster Ride Of A Biotech CEO
The Rollercoaster Ride Of A Biotech CEO Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.  Continue Reading...
  • Others Talk About Creating Good Stories; We Write Them
    Others Talk About Creating Good Stories; We Write Them

    Good storytelling is the crux of every article in Life Science leader, and our October issue is no exception. Here are a few examples of what not to miss in our next issue.

  • The Appeal Of A Good Underdog Story
    The Appeal Of A Good Underdog Story

    Like many people, I’ve always loved a good underdog story, and recently Life Science Leader has had some good ones. We also have a great CEO Corner coming up in our September issue that talks about what it’s like going from being a VC to founding and running a biopharma.

  • The Uphill Battle Of A Biotech That Switched Its Focus
    The Uphill Battle Of A Biotech That Switched Its Focus

    When Roger Crystal, M.D., says that he understands the importance of being “flexible” in the business of biotech, he’s not spouting typical ambiguous CEO-speak. In his case, he’s referring to his company’s willingness to pivot, to “pause” a path that they had invested years of time and resources to and choose a new core objective.

  • A Positive Outcome From Pharma Closures

    The large changes impacting biopharma in the Delaware Valley (i.e., Philadelphia metropolitan area) have presented a rather unique opportunity for capturing surplus biomedical research assets. As many of us know all too well, facility closures and downsizing initiatives usually result in the disposal of significant quantities of expensive chemicals, starting materials, equipment, consumables, and general and specialized industrial-grade glassware. That usually meant the safe disposal of the chemicals and the remainder of the materials being sent to landfill after appropriate washing and crushing.

  • Biosimilars Event Chairperson Not What I Expected
    Biosimilars Event Chairperson Not What I Expected

    Although I’ve rarely traveled to shows since we launched Life Science Leader in 2009, I’m not unfamiliar with fulfilling this duty as an editor; I did it for six years prior to focusing exclusively on LSL. Still, there was one element of World Biosimilar Congress that seemed foreign to me — the role of the chairperson Richard DiCicco.

  • An Entrepreneurial Approach To Funding Drug Development
    An Entrepreneurial Approach To Funding Drug Development

    The tech world is filled with stories of companies that grew from modest beginnings with minimal capital: Steve Wozniak and Steve Jobs tinkering in Jobs’ garage; Michael Dell scraping together $1,000 to buy parts and build personal computers in his dorm room at the University of Texas.

  • Advice From A Serial Pharmaceutical Entrepreneur
    Advice From A Serial Pharmaceutical Entrepreneur

    Twenty-two years after graduating college, Michael Jaharis purchased his first pharmaceutical company. That was in 1972. Four decades later he had amassed a career — and a fortune — in the pharmaceutical industry highlighted by the sales of three companies: Key Pharmaceuticals, Kos Pharmaceuticals, and Pearl Therapeutics.

  • Life Science Leader Chief Editor Invited To Attend Ringing Of NASDAQ Opening Bel
    Life Science Leader Chief Editor Invited To Attend Ringing Of NASDAQ Opening Bel

    Life Science Leader magazine’s Chief Editor, Rob Wright, was invited to attend the NASDAQ opening bell ringing ceremony on Wednesday, August 7, 2013 as a guest of the executive leadership team of NeoStem, a leader in the emerging cellular therapy industry. By Dan Schell

  • Biotech R&D Spending Jumps 5%

    Research and development (R&D) expenditures in the biotechnology industry grew five percent in 2011, bouncing back after a decline the prior year. According to a new study from BDO USA, LLP, an accounting and consulting organization, on average, biotech companies spent $50 million on R&D in 2011, up from just over $47 million invested in 2010. By Dan Schell

  • The Evolving Role Of Pharmacovigilance

    New global regulations have forced the concept of pharmacovigilance to expand beyond just identifying adverse events. Today pharmacovigilance is on the minds of every pharma and bio executive, and it starts earlier in the drug development process. By Dan Schell, Life Science Leader magazine

  • The Pharma Veteran

    Blockbusters, megamergers, government investigations — Fred Hassan has experienced them all during his nearly 40-year career.

  • How Will Outsourcing Affect Your Company In 2010?

    "Many companies are seeking to lower risk by reducing their focus on innovative medicines. This is not our path. Our strategy is to create value by accelerating the flow of innovative new medicines that provide improved outcomes for individual patients.”

  • Keeping Your Biopharm Ideas Alive

    It happens to all of us. You’re fresh from a big industry conference — in this case the BIO International Convention in Chicago — and full of new ideas. You’ve held meetings, attended seminars, and networked until your feet ached. Your head is full of new strategies and processes you can’t wait to get back and investigate. But, now comes the real challenge — assimilating all of that information you just digested. Perhaps this special edition of Life Science Leader can help.

  • There’s No Use Fighting It … Change Is Coming

    It’s a scary time to be an executive in the life sciences sector. No matter if you’re the CEO of a top pharma company or the founder of a new biotech startup, these days it seems there’s always some new policy, trend, or regulation that’s impeding your progress.

More From Dan Schell articles
Dan Schell

Dan Schell



Dan Schell is the Editorial Director of Life Science Leader magazine. In this role, he works with the publication’s internal and external writers and editors on choosing the best topics for articles as well as refining all content to meet Life Science Leader’s high editorial standards. He has been with the magazine since it was launched in 2009. Prior to focusing exclusively on Life Science Leader, he worked as an editor and copy editor for the publication’s parent company, VertMarkets. He joined the company in 2000 after 10 years of working for HealthSouth in marketing and business development and four years at an advertising agency.